Ireland-based Iterum Therapeutics, which is focused on the development and commercialization of anti-infectives for patients with infectious diseases and other acute illnesses, has raised $65m in a Series B investment round.
Biogen has acquired Remedy Pharmaceuticals' Cirara, a Phase 3 candidate in development for large hemispheric infarction (LHI).
IBM’s researchers have discovered how they can trigger the body’s immune response by using polymer-coated graphene sheets.
INC Research has agreed to acquire US-based contract research organization (CRO) inVentiv Health in all stock deal worth nearly $4.6bn.
Vivet Therapeutics, which is focused on developing novel gene therapies for rare, inherited metabolic diseases, has raised €37.5m in a Series A financing round.
Poxel has announced positive top line results of a Phase 2b trial of Imeglimin for type 2 diabetes treatment in Japan.
Sosei has agreed to make an investment in and acquire an exclusive option to potentially acquire MiNA Therapeutics, a private UK biopharmaceutical company.
AstraZeneca will develop new inhaled respiratory treatments based on Pieris Pharmaceuticals’ Anticalin platform through a collaboration that could generate more than $2bn for the US firm.
Shire has secured exclusive global rights to develop Parion Sciences' Phase II-stage epithelial sodium channel (ENaC) inhibitor P-321 for the potential treatment of dry eye.
Takeda Pharmaceutical has entered into a multi-year partnership with Harrington Discovery Institute at University Hospitals in Cleveland, Ohio to advance the development of rare disease rherapeutics.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.